HomeCompareSHPMY vs EQR

SHPMY vs EQR: Dividend Comparison 2026

SHPMY yields 3.82% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SHPMY wins by $1408.60M in total portfolio value
10 years
SHPMY
SHPMY
● Live price
3.82%
Share price
$7.60
Annual div
$0.29
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1408.65M
Annual income
$1,341,128,296.97
Full SHPMY calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — SHPMY vs EQR

📍 SHPMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHPMYEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHPMY + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHPMY pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHPMY
Annual income on $10K today (after 15% tax)
$324.34/yr
After 10yr DRIP, annual income (after tax)
$1,139,959,052.42/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, SHPMY beats the other by $1,139,954,398.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHPMY + EQR for your $10,000?

SHPMY: 50%EQR: 50%
100% EQR50/50100% SHPMY
Portfolio after 10yr
$704.35M
Annual income
$670,566,886.29/yr
Blended yield
95.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

SHPMY
No analyst data
Altman Z
1.9
Piotroski
5/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHPMY buys
0
EQR buys
0
No recent congressional trades found for SHPMY or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHPMYEQR
Forward yield3.82%5.87%
Annual dividend / share$0.29$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%15.8%
Portfolio after 10y$1408.65M$47.8K
Annual income after 10y$1,341,128,296.97$5,475.61
Total dividends collected$1403.79M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: SHPMY vs EQR ($10,000, DRIP)

YearSHPMY PortfolioSHPMY Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$11,463$763.16$11,380$679.82+$83.00SHPMY
2$13,901$1,635.18$13,014$837.25+$887.00SHPMY
3$18,580$3,706.34$14,961$1,036.20+$3.6KSHPMY
4$29,141$9,259.81$17,297$1,289.22+$11.8KSHPMY
5$58,326$27,145.47$20,121$1,613.15+$38.2KSHPMY
6$163,965$101,556.29$23,561$2,030.84+$140.4KSHPMY
7$709,076$533,633.18$27,783$2,573.54+$681.3KSHPMY
8$5,072,218$4,313,507.31$33,013$3,284.39+$5.04MSHPMY
9$63,101,541$57,674,267.04$39,547$4,223.51+$63.06MSHPMY
10$1,408,646,945$1,341,128,296.97$47,791$5,475.61+$1408.60MSHPMY

SHPMY vs EQR: Complete Analysis 2026

SHPMYStock

Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People's Republic of China. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including oncology, cerebrocardiovascular, CNS, general infection, immunology, digestive and metabolism, and respiratory. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores; online drug business; and provision of consulting services, assets management operations, as well as clinical trials, medical aid, physicians and patients' education, e-prescription management, and remote and cloud hospitals. Further, the company manufactures and trades in medicines. It operates approximately 2,000 retail chain pharmacies in 24 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.

Full SHPMY Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this SHPMY vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHPMY vs SCHDSHPMY vs JEPISHPMY vs OSHPMY vs KOSHPMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.